VKORC1 and CYP2C9 Polymorphism Detection Kit
VKORC1&CYP2C9or Warfarin Sensitivity Genotyping Kit Product Advantages: 1.High specificity: the Taqman-MGB probe method can effectively improve the specificity of genotyping. 2.High accuracy: paraffin seal sample, the whole process in a closed tube, with β-actin internal control system,...
VKORC1&CYP2C9or Warfarin Sensitivity Genotyping Kit
High specificity: the Taqman-MGB probe method can effectively improve the specificity of genotyping.
High accuracy: paraffin seal sample, the whole process in a closed tube, with β-actin internal control system, effectively prevent product contamination and false negative.
High sensitivity: accurate classification of CYP2C19 gene in samples with low to 1ng/ L DNA can be obtained.
Simple and fast: the kit is easy to operate and the detection period is short (1.5 hours), and the result is intuitive and reliable.
◆About VKORC1 & CYP2C9 or Warfarin Sensitivity Genotyping
Warfarin (Coumadin) is the most widely prescribed oral anticoagulant drug for the prevention and treatment of thrombotic disorders in North America1 . Warfarin is a potent inhibitor of VKORC1 (vitamin K epoxide reductase complex, subunit 1), which is required for converting to Vitamin K to its reduced form (VitKH2). Anticoagulation occurs when Warfarin inhibits VKOR, decreasing the amount of VitKH2 available to activate vitamin K-dependent coagulation factors II, VII, IX, and X2,3 . While Warfarin is a well-accepted therapy for many conditions, it has some serious side effects including excessive bleeding that can be life-threatening. Because of genetic variations, different people may response to Warfarin differently and thus be under dosed or overdosed. Patients with a variation, -1639G>A, in the promoter region of VKORC1 gene are more sensitive to warfarin and need lower doses than those without the variation. The CYP2C9 gene encodes one of the main enzymes involved in metabolizing warfarin into inactive hydroxylated metabolites. Several CYP2C9 alleles such as CYP2C9*2 and CYP2C9*3 are associated with reduced enzyme activity to convert warfarin into inactive form. Patients carrying at least one copy of such a variant allele will need a lower daily warfarin dose than those having normal CYP2C9 activity.
1. Holbrook AM et al. (2005). Systematic overview of warfarin and its drug and food interactions. Arch. Intern. Med. 165:1095
2. Ansell J at al. (2008). Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 133(6 Suppl):160S
3. Moyer TP at al. (2009). Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. Mayo Clin Proc. 84:1079